EverolimuS-ElUtinG BioresorbAble VasculaR Scaffolds vErsus EVerolimus-Eluting Stents in Patients With Diabetes Mellitus
Phase of Trial: Phase IV
Latest Information Update: 18 Apr 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery restenosis
- Focus Adverse reactions
- Acronyms SUGAR-EVE
- 12 Apr 2017 Status changed from recruiting to discontinued.
- 24 Oct 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Apr 2018.
- 05 Apr 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.